{
    "prompt": "\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0008350\nAge: 63\nGender: Female\nSample ID: P-0008350-T02-IM5\nGene Panel: IMPACT410\nCancer Type: Colon Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 50.0%\n=============\nDNA Variants:\nANKRD11 c.2612A>C (p.D871A) - in 9.00% of 221 reads\nARID1B c.4675T>G (p.F1559V) - in 7.00% of 153 reads\nBRAF c.1799T>A (p.V600E) - in 40.00% of 175 reads\nCCND1 c.27A>T (p.E9D) - in 8.00% of 123 reads\nDIS3 c.1881_1883dup (p.G628dup) - in 26.00% of 238 reads\nEPHA5 c.1857G>A (p.W619*) - in 28.00% of 175 reads\nINHA c.179G>A (p.R60Q) - in 20.00% of 251 reads\nNF1 c.7427A>T (p.Y2476F) - in 41.00% of 108 reads\nPARP1 c.1055A>C (p.K352T) - in 7.00% of 142 reads\nPMS1 c.545T>G (p.L182R) - in 22.00% of 199 reads\nPOLE c.6775C>T (p.R2259W) - in 30.00% of 125 reads\nPTPRD c.3160T>C (p.Y1054H) - in 21.00% of 123 reads\nRNF43 c.1322delC (p.P441Lfs*61) - in 48.00% of 65 reads\nSMAD4 c.1609G>T (p.D537Y) - in 32.00% of 124 reads\nCNA Data:\nNo CNA data found.\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Colon Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Vemurafenib\",\n    \"Prior Treatment or Resistance Status\": \"Not specified\",\n    \"Genomic Features\": \"BRAF V600E mutation\",\n    \"FDA-approval status\": \"FDA-approved for BRAF V600E-mutant metastatic colorectal cancer\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208362s000lbl.pdf\"\n  }\n}"
}